Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Medicines Patent Pool: Transparency is essential to access to medicines

In this viewpoint for Medicines Patent Pool's "10 Years of MPP" campaign, Executive Director Jayasree K. Iyer discusses the need for transparency from pharmaceutical companies in order to improve access to medicine.

Date

01 September 2020

Direct links

Read the full viewpoint

In this piece, Dr. Iyer explains the relationship between the Access to Medicine Foundation and Medicines Patent Pool (MPP), which has become the main driving force behind voluntary licensing in the pharmaceutical industry.

Whether medicines, vaccines and other products reach the people who need them, especially those in low- and middle-income countries, depends on the strategic choices companies make to support affordable access. This viewpoint stresses the need for pharma companies to be transparent about their activities in order to make their medicines more accessible and affordable.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved